# Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT05479994** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BeiGene** · enrollment: 100 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Small Lymphocytic Lymphoma
- Relapsed Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** BGB-11417

## Key facts

- **NCT ID:** NCT05479994
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-25
- **Primary completion:** 2025-01-24
- **Final completion:** 2027-08-25
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05479994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05479994, "Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05479994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*